rabeprazol actavis magasýruþolin tafla 10 mg
actavis group ptc ehf. - rabeprazolum natríum - magasýruþolin tafla - 10 mg
rabeprazol actavis magasýruþolin tafla 20 mg
actavis group ptc ehf. - rabeprazolum natríum - magasýruþolin tafla - 20 mg
rabeprazol krka magasýruþolin tafla 10 mg
krka sverige ab - rabeprazolum natríum - magasýruþolin tafla - 10 mg
rabeprazol krka magasýruþolin tafla 20 mg
krka sverige ab - rabeprazolum natríum - magasýruþolin tafla - 20 mg
rabeprazol medical valley magasýruþolin tafla 10 mg
medical valley invest ab - rabeprazolum natríum - magasýruþolin tafla - 10 mg
singulair filmuhúðuð tafla 10 mg
n.v. organon* - montelukastum natríum - filmuhúðuð tafla - 10 mg
warfarin teva tafla 3 mg
teva b.v.* - warfarinum natríum - tafla - 3 mg
zinacef stungulyfs-/innrennslisstofn, lausn 1,5 g
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1,5 g
zinacef stungulyfs-/innrennslisstofn, lausn 750 mg
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - Æxlishemjandi lyf - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.